safinamide (Xadago)
Classes: Antiparkinson Agents, Adjunct; Antiparkinson Agents, MAO Type B Inhibitors; Glutamate Inhibitors
Dosing and uses of Xadago (safinamide)
Parkinson Disease
Pending FDA approval for adjunctive therapy for patients with parkinson disease at any stage
Pharmacology of Xadago (safinamide)
Mechanism of action
Elicits dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of the excessive release of glutamate
